Terumo Delivers Double-Digit Profit Growth and Raises Dividend on Robust FY2026 Results

The latest announcement is out from Terumo ( (JP:4543) ).

Terumo reported strong results for the fiscal year ended March 31, 2026, with revenue rising 9.2% to ¥1.13 trillion and operating profit up 11.8%, while profit attributable to owners of the parent climbed 16.2% as margins improved and adjusted operating profit reached ¥219.4 billion. The company’s equity base expanded significantly as total assets grew to ¥2.31 trillion, and it increased its annual dividend to ¥30 per share while signaling further growth by guiding for fiscal 2027 revenue of ¥1.239 trillion and a 21.6% rise in profit to owners, implying continued earnings momentum and higher shareholder returns.

Operating cash flow strengthened to ¥230.9 billion even as investing outflows increased, reflecting active capital deployment and leaving cash and equivalents at ¥280.5 billion at year-end. Terumo also announced a planned dividend hike to ¥36 per share for the year ending March 2027, underscoring management’s confidence in earnings growth and supporting its positioning as a stable, yield-enhancing name in the global medtech sector.

The most recent analyst rating on (JP:4543) stock is a Buy with a Yen2500.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.

More about Terumo

Terumo Corporation is a Japan-based medical technology company listed on the Tokyo Stock Exchange that develops and manufactures devices for healthcare, including products used in hospitals, clinics, and other care settings worldwide. The group focuses on driving growth in its core medical segments while maintaining a conservative balance sheet and steady returns to shareholders through dividends.

Average Trading Volume: 5,727,186

Technical Sentiment Signal: Sell

Current Market Cap: Yen2851.6B

For detailed information about 4543 stock, go to TipRanks’ Stock Analysis page.